GERON CORPGERNEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
Revenue
$23.0K
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
-77.7%
GERON CORP Q4 FY2023 Financial Summary
GERON CORP reported revenue of $23.0K (down 77.7% YoY) for Q4 FY2023, with a net profit of N/A (down 21.9% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $23.0K |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2023 |
GERON CORP Annual Revenue by Year
GERON CORP annual revenue history includes year-by-year totals (for example, 2023 revenue was $237.0K).
| Year | Annual Revenue |
|---|---|
| 2023 | $237.0K |
| 2022 | $596.0K |
GERON CORP Quarterly Revenue & Net Profit History
GERON CORP results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $47.2M | +67.1% | $-18.4M | -39.0% |
| Q2 FY2025 | $49.0M | +5459.6% | $-16.4M | -33.4% |
| Q1 FY2025 | $39.6M | +12927.3% | $-19.8M | -50.1% |
| Q3 FY2024 | $28.3M | +17138.4% | $-26.4M | -93.5% |
| Q2 FY2024 | $882.0K | +2941.4% | $-67.4M | -7639.8% |
| Q1 FY2024 | $304.0K | +1347.6% | $-55.4M | -18220.4% |
| Q4 FY2023 | $23.0K | -77.7% | N/A | N/A |
| Q3 FY2023 | $164.0K | -44.8% | $-44.8M | -27320.1% |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $164000 | $23000 | $304000 | $882000 | $28.3M | $39.6M | $49.0M | $47.2M |
| YoY Growth | -44.8% | -77.7% | 1347.6% | 2941.4% | 17138.4% | 12927.3% | 5459.6% | 67.1% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $413.0M | $394.1M | $482.1M | $449.4M | $444.9M | $562.5M | $555.2M | $567.4M |
| Liabilities | $122.4M | $146.1M | $137.2M | $142.7M | $152.7M | $294.2M | $295.7M | $318.7M |
| Equity | $290.6M | $247.9M | $344.9M | $306.7M | $292.3M | $268.2M | $259.5M | $248.7M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-50.8M | $-167.7M | $-62.3M | $-53.5M | $-58.9M | $-48.0M | $-27.4M | $-13.6M |